AstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest ...
Furthermore, the leading banks including JPMorgan, Goldman Sachs, and Citi have pointed out the euro as one of the most ...
AstraZeneca's Enhertu breast cancer drug added to China's state insurance list
AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, ...
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...
AstraZeneca asthma drug more effective during attack than steroids, study finds
AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that ...
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
AstraZeneca Names A MSK Leader To Global Cancer Post
Dr. Bob Li, a top Asian leader from the New York-based Memorial Sloan Kettering Cancer Center, has become global head of ...
AstraZeneca Loses Covid-Shot Religious Job Accommodation Lawsuit
AstraZeneca Pharmaceuticals LP violated federal and Ohio law when it denied a Christian sales specialist an exemption from ...
NDTV18 小时
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the ...
AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades
AstraZeneca Plc’s recent share-price rout has gone so far that the pharma stock has shaken off the last of its bearish ...
We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
The market seemed underwhelmed by last week's earnings announcement from AstraZeneca PLC ( LON:AZN) despite the healthy ...
AstraZeneca的Tagrisso获得CHMP推荐在欧盟获批
AstraZeneca PLC (LSE/STO/Nasdaq: AZN) 的药物Tagrisso已获得欧洲药品管理局 (EMA)人用药品委员会 (CHMP)的批准推荐。 这项推荐是针对特定EGFR突变的局部晚期、不可切除非小细胞肺癌 (NSCLC)成年患者的治疗，这些患者在铂类化疗放疗期间或之后未出现疾病进展。